Abcam, ab245709, Human Biglycan ELISA Kit

Size: 1 x 96Tests
Human Biglycan ELISA Kit is a single-wash 90-min Simplestep used to quantify Human Biglycan with a sensitivity of 32 pg/ml. The assay uses a simple mix-wash-read protocol with just one incubation and one wash step. - Colorimetric Sandwich ELISA - 450 nm readout : works on any standard plate reader - Design your own immunoassay: we also offer the conjugation-ready antibody pair
Key facts
Detection method:Colorimetric,
Sample types:Tissue Extracts,
Reacts with:Human,
Assay type:Sandwich (quantitative),
Sensitivity:= 32 pg/mL,
Range:156.25 - 10000 pg/mL,
Assay time:1h 30m,
Assay Platform:Pre-coated microplate (12 x 8 well strips)

Product details:
Human Biglycan ELISA Kit (ab245709) is a single-wash 90 min sandwich ELISA designed for the quantitative measurement of Biglycan protein in tissue extracts. It uses our proprietary SimpleStep ELISA® technology. Quantitate Human Biglycan with 32 pg/ml sensitivity.
SimpleStep ELISA® technology employs capture antibodies conjugated to an affinity tag that is recognized by the monoclonal antibody used to coat our SimpleStep ELISA® plates. This approach to sandwich ELISA allows the formation of the antibody-analyte sandwich complex in a single step, significantly reducing assay time. See the SimpleStep ELISA® protocol summary in the image section for further details. Our SimpleStep ELISA® technology provides several benefits:
- Single-wash protocol reduces assay time to 90 minutes or less
- High sensitivity, specificity and reproducibility from superior antibodies
- Fully validated in biological samples
- 96-wells plate breakable into 12 x 8 wells strips
A 384-well SimpleStep ELISA® microplate (
ab203359
) is available to use as an alternative to the 96-well microplate provided with SimpleStep ELISA® kits.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Biglycan also known as BGN is a small leucine-rich proteoglycan with a molecular weight of roughly 38 kDa. Researchers frequently observe Biglycan in tissues such as bone cartilage and vasculature. The protein interacts with several other molecules in the extracellular matrix (ECM) including collagen and elastin to maintain the structural integrity of tissues. Through these interactions Biglycan plays an important role in supporting cell attachment and matrix organization.
Biological function summary
The protein Biglycan influences cellular processes such as growth and differentiation. It is part of a complex network within the ECM that modulates cell signaling. Biglycan interacts with growth factors like transforming growth factor-beta (TGF-beta) and binds to Toll-like receptors (TLRs) affecting immune responses. These capabilities reveal Biglycan’s involvement in tissue development and repair.
Pathways
Extracellular matrix modulation shows a significant role for Biglycan. It is involved in the TGF-beta signaling pathway and the inflammatory pathway mediated by TLRs. Through these pathways Biglycan interacts with proteins such as decorin and fibromodulin contributing to the regulation of collagen fibrillogenesis and inflammatory responses. Its role in these pathways highlights Biglycan’s influence in cellular communication and matrix regulation.
Biglycan has associations with osteoarthritis and muscular dystrophy. In osteoarthritis researchers observe altered expression levels of Biglycan which affects cartilage integrity. In muscular dystrophy the protein’s connection to dystrophin an important structural protein is noted. These associations illustrate Biglycan's impact on disease progression and its potential as a therapeutic target.